Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S295000
Reexamination Certificate
active
07960386
ABSTRACT:
The invention relates to pyridin-2-one compounds of general formula (I)in whichA represents a 4- to 6-membered hydrocarbon chain that can have 1 or 2 methyl groups as substituents, wherein 1 or 2 carbon atoms can be replaced by oxygen, a carbonyl group or sulfur, and the hydrocarbon chain can have a double bond or a triple bond;R1, R2, R3and R4have the meanings as cited in the claims and in the description.The invention also relates to the tautomers of compounds I and the physiologically acceptable salts of the compounds I and their tautomers.The invention also relates to the use of these compounds for treating diseases that respond to the influence of dopamine D3receptor antagonists or agonists.
REFERENCES:
patent: 5958923 (1999-09-01), Hellendahl et al.
patent: 6090807 (2000-07-01), Hellendahl et al.
patent: 6342604 (2002-01-01), Hellendahl et al.
patent: 2006/0235004 (2006-10-01), Geneste et al.
patent: WO 96/02246 (1996-02-01), None
patent: WO 03/002543 (2003-01-01), None
patent: WO 2004/080981 (2004-09-01), None
Le Foll et al., PubMed Abstract (Expert Opinion Investig Drugs, 16(1):45-57), Jan. 2007.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Schwartz, J.C. et al., “The Dopamine D3 Receptor as a Target for Antipsychotics” in H.Y. Meltzer (ed.) Novel Antipsychotic Drugs (Raven Press Ltd., New York 1992), 135-143.
Joyce, J. N., “Dopamine D3 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs”, Pharmacology & Therapeutics 90, 2001, 231-259.
Sokoloff, P. et al., “Localization and Function of the D3 Dopamine Receptor”, Arzneim.-Forsch/Drgu Res. 42(1), No. 2a, 1992.
Sokoloff, P. et al., “Molecular Cloning and Characterization of a Novel Dopamine Receptor D3 as a Target for Neuroleptics”, Nature 347, 1990, 146-150.
Benoit et al., “Altered Feeding Responses in Mice with Targeted Disruption of the Dopamine-3 Receptor Gene,” Behavioral Neuroscience, 2003, vol. 117, No. 1, pp. 46-54.
Joyce, “Dopamine D3 receptor as therapeutic target for antipsychotic and antiparkinsonian drug,” Pharmacology & Therapeutics, 2001, vol. 90, pp. 231-259.
Muhlbauer et al., “Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology,” Acta. Physicol. Scand., 2000, vol. 168, pp. 219-223.
Rogoz et al., “Anxiolytic-Like Effects of Preferential Dopamine D3 Receptor Agonists in an Animal Model,” Polish Journal of Pharmacology, 2003, vol. 55, pp. 449-454.
Heidbreder et al., “The role of central D3 receptors in drug addiction: a review of pharmacological evidence,” Brain Research Reviews, 2005, vol. 49, pp. 77-105.
Braje Wilfried
Geneste Hervé
Haupt Andreas
Abbott & GmbH & Co. KG
Mueller Lisa V.
Polsinelli Shughart PC
Rao Deepak
LandOfFree
Pyridin-2-one compounds and their use as modulators of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridin-2-one compounds and their use as modulators of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridin-2-one compounds and their use as modulators of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738387